Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer
Identifieur interne : 006B67 ( Main/Exploration ); précédent : 006B66; suivant : 006B68Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer
Auteurs : Chee K. Lee [Australie] ; Michael Friedlander [Australie] ; Chris Brown [Australie] ; Val J. Gebski [Australie] ; Alexander Georgoulopoulos [Autriche] ; Ignace Vergote [Belgique] ; Sandro Pignata [Italie] ; Nicoletta Donadello [Italie] ; Barbara Schmalfeldt [Allemagne] ; Remy Delva [France] ; Mansoor Raza Mirza [Danemark] ; Philippe Sauthier [Canada] ; Eric Pujade-Lauraine [France] ; Sarah J. Lord [Australie] ; R. John Simes [Australie]Source :
- Journal of the National Cancer Institute [ 0027-8874 ] ; 2011.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
We used data from 886 patients from the CAELYX in Platinum Sensitive Ovarian Patients (CALYPSO) trial, recruited between April 2005 and September 2007, to examine the role of early decline in cancer antigen 125 (CA125) and early tumor response as prognostic factors and surrogates for superiority of treatment with carboplatin-pegylated liposomal doxorubicin (CPLD) compared with carboplatin- paclitaxel (CP) in a landmark analysis. Progression-free survival (PFS) was estimated by Kaplan-Meier analyses. We used univariate and multivariable Cox proportional hazards analyses to assess early decline and early response as surrogates for CPLD treatment benefit compared with CP. All statistical tests were two-sided. Early decline (defined as rate of CA125 decrease of at least 50% per month) was associated with improved PFS (adjusted hazard ratio [HR] for progression = 0.81, 95% confidence interval [CI] = 0.67 to 0.97, P = .02) but early response (complete or partial responses) was not. CPLD was associated with improved PFS compared with CP (HR = 0.82, 95% CI = 0.69 to 0.96, P = .01 However, fewer CPLD patients had an early decline (161 [37.4%] vs 233 [51.2%], P < .001) or an early response (146 [33.9%] vs 176 [38.7%], P = .14) compared with CP patients. The PFS for CPLD patients did not change statistically significantly after adjustment for early decline (adjusted HR = 0.80, 95% CI = 0.68 to 0.94, P = .007). These findings are opposite to what would be expected if these markers were good surrogates for treatment benefit.
Affiliations:
- Allemagne, Australie, Autriche, Belgique, Canada, Danemark, France, Italie
- Bavière, District de Haute-Bavière, Hovedstaden, Nouvelle-Galles du Sud, Pays de la Loire, Québec, Île-de-France
- Angers, Copenhague, Montréal, Munich, Paris, Sydney
- Université Louis-et-Maximilien de Munich, Université Paris-Descartes, Université de Sydney
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001927
- to stream PascalFrancis, to step Curation: 004629
- to stream PascalFrancis, to step Checkpoint: 001B64
- to stream Main, to step Merge: 007015
- to stream Main, to step Curation: 006B67
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer</title><author><name sortKey="Lee, Chee K" sort="Lee, Chee K" uniqKey="Lee C" first="Chee K." last="Lee">Chee K. Lee</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>NHMRC Clinical Trials Centre, University of Sydney</s1><s2>Sydney, NSW</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Prince of Wales Hospital, Institute of Medical Oncology</s1><s2>Randwick, Sydney</s2><s3>AUS</s3><sZ>2 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Brown, Chris" sort="Brown, Chris" uniqKey="Brown C" first="Chris" last="Brown">Chris Brown</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>NHMRC Clinical Trials Centre, University of Sydney</s1><s2>Sydney, NSW</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Gebski, Val J" sort="Gebski, Val J" uniqKey="Gebski V" first="Val J." last="Gebski">Val J. Gebski</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>NHMRC Clinical Trials Centre, University of Sydney</s1><s2>Sydney, NSW</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Georgoulopoulos, Alexander" sort="Georgoulopoulos, Alexander" uniqKey="Georgoulopoulos A" first="Alexander" last="Georgoulopoulos">Alexander Georgoulopoulos</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Private Medical University</s1><s2>Salzburg</s2><s3>AUT</s3><sZ>5 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Private Medical University</wicri:noRegion></affiliation></author><author><name sortKey="Vergote, Ignace" sort="Vergote, Ignace" uniqKey="Vergote I" first="Ignace" last="Vergote">Ignace Vergote</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University Hospital Leuven, Gynaecological Oncology</s1><s2>Leuven</s2><s3>BEL</s3><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Pignata, Sandro" sort="Pignata, Sandro" uniqKey="Pignata S" first="Sandro" last="Pignata">Sandro Pignata</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>National Cancer Institute, Division of Medical Oncology B</s1><s2>Naples</s2><s3>ITA</s3><sZ>7 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Donadello, Nicoletta" sort="Donadello, Nicoletta" uniqKey="Donadello N" first="Nicoletta" last="Donadello">Nicoletta Donadello</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Obstetrics and Gynecology, University of Varese</s1><s2>Varese</s2><s3>ITA</s3><sZ>8 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Varese</wicri:noRegion></affiliation></author><author><name sortKey="Schmalfeldt, Barbara" sort="Schmalfeldt, Barbara" uniqKey="Schmalfeldt B" first="Barbara" last="Schmalfeldt">Barbara Schmalfeldt</name><affiliation wicri:level="4"><inist:fA14 i1="07"><s1>Obstetrics and Gynecology, Technical University of Munich</s1><s2>Munich</s2><s3>DEU</s3><sZ>9 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement><settlement type="city">Munich</settlement></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Delva, Remy" sort="Delva, Remy" uniqKey="Delva R" first="Remy" last="Delva">Remy Delva</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Anticancer Centre Paul Papin</s1><s2>Angers</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Angers</settlement></placeName></affiliation></author><author><name sortKey="Raza Mirza, Mansoor" sort="Raza Mirza, Mansoor" uniqKey="Raza Mirza M" first="Mansoor" last="Raza Mirza">Mansoor Raza Mirza</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Department of Oncology, The Finsen Centre, Copenhagen University Hospital - Rigshospitalet</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>11 aut.</sZ></inist:fA14><country>Danemark</country><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Sauthier, Philippe" sort="Sauthier, Philippe" uniqKey="Sauthier P" first="Philippe" last="Sauthier">Philippe Sauthier</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>CHUM-Hopital Notre Dame</s1><s2>Montreal</s2><s3>CAN</s3><sZ>12 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name><affiliation wicri:level="4"><inist:fA14 i1="11"><s1>Universite Paris Descartes, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu, Oncologie</s1><s2>Paris</s2><s3>FRA</s3><sZ>13 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Paris-Descartes</orgName></affiliation></author><author><name sortKey="Lord, Sarah J" sort="Lord, Sarah J" uniqKey="Lord S" first="Sarah J." last="Lord">Sarah J. Lord</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>NHMRC Clinical Trials Centre, University of Sydney</s1><s2>Sydney, NSW</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Simes, R John" sort="Simes, R John" uniqKey="Simes R" first="R. John" last="Simes">R. John Simes</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>NHMRC Clinical Trials Centre, University of Sydney</s1><s2>Sydney, NSW</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0435844</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0435844 INIST</idno><idno type="RBID">Pascal:11-0435844</idno><idno type="wicri:Area/PascalFrancis/Corpus">001927</idno><idno type="wicri:Area/PascalFrancis/Curation">004629</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001B64</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001B64</idno><idno type="wicri:doubleKey">0027-8874:2011:Lee C:early:decline:in</idno><idno type="wicri:Area/Main/Merge">007015</idno><idno type="wicri:Area/Main/Curation">006B67</idno><idno type="wicri:Area/Main/Exploration">006B67</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer</title><author><name sortKey="Lee, Chee K" sort="Lee, Chee K" uniqKey="Lee C" first="Chee K." last="Lee">Chee K. Lee</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>NHMRC Clinical Trials Centre, University of Sydney</s1><s2>Sydney, NSW</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Prince of Wales Hospital, Institute of Medical Oncology</s1><s2>Randwick, Sydney</s2><s3>AUS</s3><sZ>2 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Brown, Chris" sort="Brown, Chris" uniqKey="Brown C" first="Chris" last="Brown">Chris Brown</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>NHMRC Clinical Trials Centre, University of Sydney</s1><s2>Sydney, NSW</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Gebski, Val J" sort="Gebski, Val J" uniqKey="Gebski V" first="Val J." last="Gebski">Val J. Gebski</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>NHMRC Clinical Trials Centre, University of Sydney</s1><s2>Sydney, NSW</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Georgoulopoulos, Alexander" sort="Georgoulopoulos, Alexander" uniqKey="Georgoulopoulos A" first="Alexander" last="Georgoulopoulos">Alexander Georgoulopoulos</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Private Medical University</s1><s2>Salzburg</s2><s3>AUT</s3><sZ>5 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Private Medical University</wicri:noRegion></affiliation></author><author><name sortKey="Vergote, Ignace" sort="Vergote, Ignace" uniqKey="Vergote I" first="Ignace" last="Vergote">Ignace Vergote</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University Hospital Leuven, Gynaecological Oncology</s1><s2>Leuven</s2><s3>BEL</s3><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Pignata, Sandro" sort="Pignata, Sandro" uniqKey="Pignata S" first="Sandro" last="Pignata">Sandro Pignata</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>National Cancer Institute, Division of Medical Oncology B</s1><s2>Naples</s2><s3>ITA</s3><sZ>7 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Donadello, Nicoletta" sort="Donadello, Nicoletta" uniqKey="Donadello N" first="Nicoletta" last="Donadello">Nicoletta Donadello</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Obstetrics and Gynecology, University of Varese</s1><s2>Varese</s2><s3>ITA</s3><sZ>8 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Varese</wicri:noRegion></affiliation></author><author><name sortKey="Schmalfeldt, Barbara" sort="Schmalfeldt, Barbara" uniqKey="Schmalfeldt B" first="Barbara" last="Schmalfeldt">Barbara Schmalfeldt</name><affiliation wicri:level="4"><inist:fA14 i1="07"><s1>Obstetrics and Gynecology, Technical University of Munich</s1><s2>Munich</s2><s3>DEU</s3><sZ>9 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement><settlement type="city">Munich</settlement></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Delva, Remy" sort="Delva, Remy" uniqKey="Delva R" first="Remy" last="Delva">Remy Delva</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Anticancer Centre Paul Papin</s1><s2>Angers</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Angers</settlement></placeName></affiliation></author><author><name sortKey="Raza Mirza, Mansoor" sort="Raza Mirza, Mansoor" uniqKey="Raza Mirza M" first="Mansoor" last="Raza Mirza">Mansoor Raza Mirza</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Department of Oncology, The Finsen Centre, Copenhagen University Hospital - Rigshospitalet</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>11 aut.</sZ></inist:fA14><country>Danemark</country><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Sauthier, Philippe" sort="Sauthier, Philippe" uniqKey="Sauthier P" first="Philippe" last="Sauthier">Philippe Sauthier</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>CHUM-Hopital Notre Dame</s1><s2>Montreal</s2><s3>CAN</s3><sZ>12 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name><affiliation wicri:level="4"><inist:fA14 i1="11"><s1>Universite Paris Descartes, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu, Oncologie</s1><s2>Paris</s2><s3>FRA</s3><sZ>13 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Paris-Descartes</orgName></affiliation></author><author><name sortKey="Lord, Sarah J" sort="Lord, Sarah J" uniqKey="Lord S" first="Sarah J." last="Lord">Sarah J. Lord</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>NHMRC Clinical Trials Centre, University of Sydney</s1><s2>Sydney, NSW</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Simes, R John" sort="Simes, R John" uniqKey="Simes R" first="R. John" last="Simes">R. John Simes</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>NHMRC Clinical Trials Centre, University of Sydney</s1><s2>Sydney, NSW</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author></analytic><series><title level="j" type="main">Journal of the National Cancer Institute</title><title level="j" type="abbreviated">J. Natl. Cancer Inst.</title><idno type="ISSN">0027-8874</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of the National Cancer Institute</title><title level="j" type="abbreviated">J. Natl. Cancer Inst.</title><idno type="ISSN">0027-8874</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>CA 125 antigen</term><term>Cancerology</term><term>Carbohydrate antigen</term><term>Human</term><term>Ovary cancer</term><term>Prognosis</term><term>Progression free survival</term><term>Relapse</term><term>Tumor associated antigen</term><term>Tumoral marker</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cancer de l'ovaire</term><term>Antigène associé tumeur</term><term>Antigène CA 125</term><term>Marqueur tumoral</term><term>Récidive</term><term>Cancérologie</term><term>Antigène carbohydrate</term><term>Pronostic</term><term>Homme</term><term>Survie sans progression</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We used data from 886 patients from the CAELYX in Platinum Sensitive Ovarian Patients (CALYPSO) trial, recruited between April 2005 and September 2007, to examine the role of early decline in cancer antigen 125 (CA125) and early tumor response as prognostic factors and surrogates for superiority of treatment with carboplatin-pegylated liposomal doxorubicin (CPLD) compared with carboplatin- paclitaxel (CP) in a landmark analysis. Progression-free survival (PFS) was estimated by Kaplan-Meier analyses. We used univariate and multivariable Cox proportional hazards analyses to assess early decline and early response as surrogates for CPLD treatment benefit compared with CP. All statistical tests were two-sided. Early decline (defined as rate of CA125 decrease of at least 50% per month) was associated with improved PFS (adjusted hazard ratio [HR] for progression = 0.81, 95% confidence interval [CI] = 0.67 to 0.97, P = .02) but early response (complete or partial responses) was not. CPLD was associated with improved PFS compared with CP (HR = 0.82, 95% CI = 0.69 to 0.96, P = .01 However, fewer CPLD patients had an early decline (161 [37.4%] vs 233 [51.2%], P < .001) or an early response (146 [33.9%] vs 176 [38.7%], P = .14) compared with CP patients. The PFS for CPLD patients did not change statistically significantly after adjustment for early decline (adjusted HR = 0.80, 95% CI = 0.68 to 0.94, P = .007). These findings are opposite to what would be expected if these markers were good surrogates for treatment benefit.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>Belgique</li><li>Canada</li><li>Danemark</li><li>France</li><li>Italie</li></country><region><li>Bavière</li><li>District de Haute-Bavière</li><li>Hovedstaden</li><li>Nouvelle-Galles du Sud</li><li>Pays de la Loire</li><li>Québec</li><li>Île-de-France</li></region><settlement><li>Angers</li><li>Copenhague</li><li>Montréal</li><li>Munich</li><li>Paris</li><li>Sydney</li></settlement><orgName><li>Université Louis-et-Maximilien de Munich</li><li>Université Paris-Descartes</li><li>Université de Sydney</li></orgName></list><tree><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Lee, Chee K" sort="Lee, Chee K" uniqKey="Lee C" first="Chee K." last="Lee">Chee K. Lee</name></region><name sortKey="Brown, Chris" sort="Brown, Chris" uniqKey="Brown C" first="Chris" last="Brown">Chris Brown</name><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name><name sortKey="Gebski, Val J" sort="Gebski, Val J" uniqKey="Gebski V" first="Val J." last="Gebski">Val J. Gebski</name><name sortKey="Lord, Sarah J" sort="Lord, Sarah J" uniqKey="Lord S" first="Sarah J." last="Lord">Sarah J. Lord</name><name sortKey="Simes, R John" sort="Simes, R John" uniqKey="Simes R" first="R. John" last="Simes">R. John Simes</name></country><country name="Autriche"><noRegion><name sortKey="Georgoulopoulos, Alexander" sort="Georgoulopoulos, Alexander" uniqKey="Georgoulopoulos A" first="Alexander" last="Georgoulopoulos">Alexander Georgoulopoulos</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Vergote, Ignace" sort="Vergote, Ignace" uniqKey="Vergote I" first="Ignace" last="Vergote">Ignace Vergote</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Pignata, Sandro" sort="Pignata, Sandro" uniqKey="Pignata S" first="Sandro" last="Pignata">Sandro Pignata</name></noRegion><name sortKey="Donadello, Nicoletta" sort="Donadello, Nicoletta" uniqKey="Donadello N" first="Nicoletta" last="Donadello">Nicoletta Donadello</name></country><country name="Allemagne"><region name="Bavière"><name sortKey="Schmalfeldt, Barbara" sort="Schmalfeldt, Barbara" uniqKey="Schmalfeldt B" first="Barbara" last="Schmalfeldt">Barbara Schmalfeldt</name></region></country><country name="France"><region name="Pays de la Loire"><name sortKey="Delva, Remy" sort="Delva, Remy" uniqKey="Delva R" first="Remy" last="Delva">Remy Delva</name></region><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name></country><country name="Danemark"><region name="Hovedstaden"><name sortKey="Raza Mirza, Mansoor" sort="Raza Mirza, Mansoor" uniqKey="Raza Mirza M" first="Mansoor" last="Raza Mirza">Mansoor Raza Mirza</name></region></country><country name="Canada"><region name="Québec"><name sortKey="Sauthier, Philippe" sort="Sauthier, Philippe" uniqKey="Sauthier P" first="Philippe" last="Sauthier">Philippe Sauthier</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006B67 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006B67 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:11-0435844
|texte= Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer
}}
| This area was generated with Dilib version V0.6.33. |  |